A Phase III Trial To Evaluate The Efficacy And Safety Of MC2-01 Cream Compared To CAL/BDP Gel and Vehicle In Plaque Psoriasis Subjects

This is a multi-center, randomized, investigator-blinded, calcipotriol and betamethasone dipropionate gel and vehicle-controlled phase 3 clinical study to evaluate the efficacy and safety of MC2-01 cream in the treatment of Chinese plaque psoriasis to assess the efficacy and safety of MC2-01 cream in Chinese subjects aged ≥ 18 years with plaque psoriasis. This study includes a screening period, a treatment period, and a safety follow-up period.

NCT Number	NCT07357831
Lead Sponsor	Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. Collaborators: MC2 Therapeutics
Conditions	Plaque Psoriasis
Enrollment	537 participants
Start Date	2025-12-26
Primary Completion	2026-10-10 (estimated)
Study Completion	2026-12-17 (estimated)
Updated on ClinicalTrials.gov	2026-06-23